IN2014DN10996A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10996A
IN2014DN10996A IN10996DEN2014A IN2014DN10996A IN 2014DN10996 A IN2014DN10996 A IN 2014DN10996A IN 10996DEN2014 A IN10996DEN2014 A IN 10996DEN2014A IN 2014DN10996 A IN2014DN10996 A IN 2014DN10996A
Authority
IN
India
Prior art keywords
dna sequence
composition
targeted
alteration
minivector
Prior art date
Application number
Other languages
English (en)
Inventor
E Lynn Zechiedrich
Jonathan Fogg
Jr Daniel James Catanese
Erol Bakkalbasi
Nancy Maizel
Olivier Humbert
Original Assignee
Baylor College Medicine
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Univ Washington filed Critical Baylor College Medicine
Publication of IN2014DN10996A publication Critical patent/IN2014DN10996A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN10996DEN2014 2012-05-30 2013-05-30 IN2014DN10996A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653279P 2012-05-30 2012-05-30
PCT/US2013/043433 WO2013181440A1 (fr) 2012-05-30 2013-05-30 Minivecteurs superenroulés comme outil de réparation, de modification et de remplacement de l'adn

Publications (1)

Publication Number Publication Date
IN2014DN10996A true IN2014DN10996A (fr) 2015-09-25

Family

ID=49673908

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10996DEN2014 IN2014DN10996A (fr) 2012-05-30 2013-05-30

Country Status (10)

Country Link
US (2) US20150376645A1 (fr)
EP (1) EP2854866A4 (fr)
JP (1) JP2015523860A (fr)
KR (1) KR20150027756A (fr)
AU (1) AU2013267350A1 (fr)
BR (1) BR112014030007A2 (fr)
CA (1) CA2876860A1 (fr)
IN (1) IN2014DN10996A (fr)
MX (1) MX2014014650A (fr)
WO (1) WO2013181440A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (fr) 2011-07-22 2020-04-22 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
PT2800811T (pt) 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
ES2769310T3 (es) 2012-12-06 2020-06-25 Sigma Aldrich Co Llc Modificación y regulación del genoma basada en CRISPR
ES2901396T3 (es) 2013-03-14 2022-03-22 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
CA2910427C (fr) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Procedes et compositions d'apport pour genie genomique medie par nuclease
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
WO2015040402A1 (fr) 2013-09-18 2015-03-26 Kymab Limited Procédés, cellules et organismes
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
CA2944141C (fr) * 2014-03-28 2023-03-28 Aposense Ltd. Composes et procedes pour l'administration transmembranaire de molecules
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
EP3943507A1 (fr) 2014-04-10 2022-01-26 Seattle Children's Hospital, dba Seattle Children's Research Institute Expression transgénique liée un médicament
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016025759A1 (fr) 2014-08-14 2016-02-18 Shen Yuelei Système "knock-in" d'adn
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
CN105821072A (zh) * 2015-01-23 2016-08-03 深圳华大基因研究院 用于DNA组装的CRISPR-Cas9系统及DNA组装方法
CN108174604B (zh) 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） 用于实体瘤靶向的双特异性car t细胞
AU2016326711B2 (en) 2015-09-24 2022-11-03 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/Cas-mediated genome editing
IL294014B1 (en) 2015-10-23 2024-03-01 Harvard College Nucleobase editors and their uses
WO2017147278A1 (fr) 2016-02-25 2017-08-31 The Children's Medical Center Corporation Commutateur de classe personnalisé de gènes d'immunoglobuline dans un lymphome et un hybridome par la technologie crispr/cas9
EP3219803A1 (fr) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Transposons « sleeping beauty » améliorés, kits et procédés de transposition
EP3433363A1 (fr) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systèmes d'édition de génome comprenant des molécules d'enzyme modulant la réparation et leurs procédés d'utilisation
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
WO2017207589A1 (fr) 2016-06-01 2017-12-07 Kws Saat Se Séquences d'acides nucléiques hybrides destinées à l'ingénierie génomique
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
US10892034B2 (en) 2016-07-01 2021-01-12 Microsoft Technology Licensing, Llc Use of homology direct repair to record timing of a molecular event
WO2018005117A1 (fr) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Stockage par édition itérative d'adn
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (fr) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Proteines de fusion cas9-recombinase programmables et utilisations associees
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
WO2018069343A1 (fr) 2016-10-10 2018-04-19 Limagrain Europe Acide nucléique codant pour la résistance sm1 de la cécidomyie des blés et procédé d'utilisation
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
WO2018144097A1 (fr) 2016-11-04 2018-08-09 Akeagen Llc Animaux non humains génétiquement modifiés et méthodes de production d'anticorps à chaîne lourde uniquement
MX2019006631A (es) 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
CA3049640A1 (fr) 2017-01-09 2018-07-12 Aposense Ltd. Composes et procedes pour l'administration transmembranaire de molecules
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
US20180305701A1 (en) 2017-03-14 2018-10-25 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
WO2019014564A1 (fr) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systèmes et procédés d'intégration ciblée et d'édition du génome et détection de celle-ci à l'aide de sites d'amorçage intégrés
WO2019023680A1 (fr) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CA3078280A1 (fr) 2017-10-05 2019-04-11 Biogemma Rendement ameliore dans des plantes par surexpression d'une trehalose-6 phosphate synthase
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
EP3704140A1 (fr) 2017-10-31 2020-09-09 Vilmorin & Cie Blé comprenant des allèles restaurateurs de la fertilité masculine
US20200048716A1 (en) 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
CN111511198A (zh) * 2017-11-21 2020-08-07 孟山都技术公司 具有增强的性状的经修饰的植物
GB201805865D0 (en) 2018-04-09 2018-05-23 Innes John Centre Genes
WO2019226650A1 (fr) 2018-05-23 2019-11-28 Modernatx, Inc. Administration d'adn
US20220098612A1 (en) 2019-02-06 2022-03-31 Vilmorin & Cie New gene responsible for cytoplasmic male sterility
EP3942040A1 (fr) 2019-03-19 2022-01-26 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
US20220259611A1 (en) 2019-07-05 2022-08-18 Limagrain Europe Method for increasing yield in plants
FR3099178A1 (fr) 2019-07-24 2021-01-29 Soltis Tournesol à teneur élevée en acide oléique et procédé d’obtention
CA3151464A1 (fr) 2019-09-18 2021-03-25 Bruce C. SCHNEPP Vecteurs d'adn synthetiques et procedes d'utilisation
CN112779266A (zh) 2019-11-06 2021-05-11 青岛清原化合物有限公司 在生物体内创制新基因的方法及应用
US20230123128A1 (en) * 2020-04-03 2023-04-20 Progenitor Life Sciences Targeting tapasin and tap complex to improve cellular immune-compatibility
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
WO2021247507A1 (fr) 2020-06-01 2021-12-09 Modernatx, Inc. Variants de la phénylalanine hydroxylase et leurs utilisations
EP4337177A1 (fr) 2021-05-11 2024-03-20 Modernatx, Inc. Administration non virale d'adn pour expression prolongée de polypeptide in vivo
US20240093226A1 (en) 2021-09-10 2024-03-21 Baylor College Of Medicine Ultrapure minivectors for gene therapy
US20240100189A1 (en) 2021-09-10 2024-03-28 Twister Biotech, Inc Using minivectors to treat idiopathic pulmonary fibrosis
US20230190955A1 (en) 2021-10-21 2023-06-22 Baylor College Of Medicine Treatment of liver cancer or liver fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030965A2 (fr) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methodes de transfert genique in vivo a l'aide d'un systeme de transposon «sleeping beauty»
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2011047318A2 (fr) * 2009-10-16 2011-04-21 Baylor College Of Medicine Adn surenroulé en minicercle pour applications en thérapie génique
WO2012064970A1 (fr) * 2010-11-12 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Intégration dirigée de transgènes chez des mammifères
WO2013158309A2 (fr) * 2012-04-18 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Ciblage génique non disruptif

Also Published As

Publication number Publication date
JP2015523860A (ja) 2015-08-20
BR112014030007A2 (pt) 2017-06-27
AU2013267350A1 (en) 2015-01-29
EP2854866A1 (fr) 2015-04-08
US20140056868A1 (en) 2014-02-27
WO2013181440A1 (fr) 2013-12-05
CA2876860A1 (fr) 2013-12-05
KR20150027756A (ko) 2015-03-12
US20150376645A1 (en) 2015-12-31
EP2854866A4 (fr) 2015-12-23
MX2014014650A (es) 2015-10-14

Similar Documents

Publication Publication Date Title
IN2014DN10996A (fr)
IL273159A (en) A culture medium preparation, and a method for culturing cells or tissues by using the preparation
EA024121B9 (ru) Композиции эндорибонуклеаз и способы их использования
MX2022003477A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
MX2015004649A (es) Metodos de modificacion de celulas huesped.
EP2279243A4 (fr) Approches chimiques et génétiques combinées pour la génération de cellules souches pluripotentes induites
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
WO2012021632A3 (fr) Génération et utilisation de cellules souches pluripotentes
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
SG10201809901SA (en) Generating Pluripotent Cells De Novo
EP2633036A4 (fr) Procédés de différenciation pour la production de populations de cellules gliales
MX2012001261A (es) Medio de cultivo de celula para la expresion de proteina adamts.
IN2014MN01680A (fr)
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
MX366912B (es) Producción de vacuna recombinante en e. coli mediante conjugación enzimática.
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
MY173663A (en) Compositions and methods for biological production of fatty acid derivatives
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
MY197970A (en) Microorganisms and methods for the production of caprolactone
EP2582792A4 (fr) Milieu de cardiomyocytes avec du sérum dialysé
IN2014DN11272A (fr)
IN2012DN00852A (fr)
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins